Hypermethylation of nc886 in HPV-Positive Oropharyngeal Cancer and Its Clinical Implications: An Epigenome-Wide Association Study

Authors

Yifan Xu
Ziqiao Wang
Peng Wei
Richa Gairola
Karl T Kelsey
Andrew G Sikora
Guojun Li
Jian Gu

Publication Date

12-13-2022

Journal

Molecular Therapy Nucleic Acids

Abstract

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased rapidly in the United States, driven by rising human papillomavirus (HPV) infections in the U.S. population. HPV-positive OPSCC patients have a better prognosis than HPV-negative patients. To gain insights into the unique biology of HPV(+) OPSCC that may contribute to its clinical behaviors, we performed a multi-stage epigenome-wide methylation profiling of leukocyte and tumor DNA in OPSCC patients and compared the methylation levels of CpG sites between HPV(+) and HPV(-) OPSCC patients. We identified and validated a significantly differentially methylated region (DMR) of 1,355 bp encompassing non-coding RNA 886 (nc886) gene and its promoter region. Nc886 is hypermethylated in both leukocytes and tumor DNA of HPV(+) OPSCC patients. Homozygous knockout of nc886 by CRISPR-Cas9 in head and neck cell lines was lethal, but nc886 could be knocked out on the background of protein kinase R (PKR) knockout. Our data suggest that HPV induces nc886 hypermethylation, and nc886 acts as both a viral sensor and a tumor sensor in OPSCC patients and contribute to the better prognosis of HPV(+) OPSCC patients. Nc886 may become a therapeutic target in OPSCC.

Keywords

MT: Non-coding RNAs, oropharyngeal cancer, OPSCC, HPV, DNA methylation, non-coding RNA, nc886, PKR, leukocyte

Comments

Associated Data

PMID: 36514351